Literaturverzeichnis
zum Titelthema „Prävention in der Kardiologie; Was ist gesichert – was ist Mythos?“
Bayerisches Ärzteblatt 10/2013, Seite 488 ff.
von Professor Dr. Stephan Holmer
1. Deutscher Herzbericht 2011, Seite 37 ff. Hrsg. Deutsche Herzstiftung, Frankfurt a.M.
2. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009;16:121–137.
3. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). European Heart Journal 2012
4. Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein(a) as a cardiovascular risk factor: current status. European Heart Journal 2010; 31, 2844–2853
5. CARDIoGRAMplusC4D Consortium, Deloukas P, Kanoni S, Willenborg C, et al.
Large-scale association analysis identifies new risk loci for coronary artery disease.
Nat Genet. 2013;45:25-33
6. Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation. 2010;122:352-360
7. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with
continuous positive airway pressure: an observational study. Lancet. 2005;365:1046- 1053
8. Law MR, Morris JK, Wald NJ Et al. Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence. BMJ 1997;315:973–980
9. Estruch R, Ros E, Salas-Salvadó J et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279-1290
10. Shiroma EJ, Lee IM. Physical activity and cardiovascular health: lessons learned from epidemiological studies across age, gender, and race/ethnicity. Circulation. 2010 Aug 17;122(7):743-52
11. Bolland MJ, Avenell A, Baron JA et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010;
29;341:c3691.
12. Ye Y, Li J, Yuan Z. Effect of antioxidant vitamin supplementation on cardiovascular outcomes: a meta-analysis of randomized controlled trials. PLoS One.
2013;8(2):e56803
13. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278
14. Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903-1909
15. Silber S, Helms T, Berger H et al. Optimale Thrombozytenaggegationshemmung bei Patienten mit akutem Koronarsyndrom. Leitfaden Berufsverband Interventioneller Kardiologen 2012
16. Gwon HC, Hahn JY, Park KW et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012;125:505-513
17. Schofield JD, France M, Ammori B, Liu Y, Soran H. High-density lipoprotein cholesterol raising: does it matter? Curr Opin Cardiol. 2013;28:464-474
18. Cushman WC, Evans GW, Byington RP et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N EnglJ Med 2010;362:1575–1585
19. Parving HH, Brenner BM, McMurray JJ et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204-2213.
20. Bangalore S, Steg G, Deedwania P et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308:1340- 1349
21. Bardy GH, Lee KL, Mark DB, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. NEnglJMed 2005;352:225–237
22. Al-Khatib SM, Hellkamp A, Bardy GH et al. Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials.
JAMA. 2013;309:55-62
23. Bank AJ, Burns KV, Gage RM et al. Cardiac resynchronization therapy in the real world: comparison with the COMPANION study. J Card Fail. 2012;18:153-158.
24. Veazie PJ, Noyes K, Li Q et al. Cardiac resynchronization and quality of life in patients with minimally symptomatic heart failure. J Am Coll Cardiol. 2012;60:1940- 1944
25. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation.
European Heart Journal 2012;33:2719–2747
26. Reddy VY, Doshi SK, Sievert H et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial
Fibrillation) Trial. Circulation. 2013;127:720-729
27. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van 't Hof AW, ten Berg JM; WOEST study investigators.Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;381:1107-1115.
28. Lamberts M, Gislason GH, Olesen JB, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol 2013; doi:10.1016/j.jacc.2013.05.029. Published online
